Alternative therapies in health and medicine · 2025
Clinical Effects of the Unani Medicine Formulations Majoon and Tila Baras-e-Aswad on Plaque Psoriasis: A Single-Arm Clinical Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mobeen Abdul, Manzoor Faisel
Аннотация
BACKGROUND: Psoriasis is a chronic, autoimmune, T-cell-mediated inflammatory disease with an "onset-remission-recurrence" pattern, and is managed symptomatically, therefore the need for treatment is usually lifelong.
PRIMARY STUDY OBJECTIVE: This study aimed to evaluate the efficacy of Majoon and Tila Baras-e-Aswad, two combination formulations, consisting of herbal, mineral, and animal drugs (antioxidants, anti-psoriatic, antihistaminic, antipruritic, and skin protection with healing activities), prescribed for the treatment of Baras-e-Aswad, having a plaque psoriasis-like diagnosis in Unani medicine.
METHODS/DESIGN: Open-label single-arm and single-center clinical study with pre-and post-treatment analysis.
SETTING: Conducted in National Institute of Unani Medicine (NIUM) Hospital, Bangalore, India.
PARTICIPANTS: A total of 36 patients with plaque psoriasis with mild to moderate severity and aged 18-60 were included.
INTERVENTIONS: The intervention formulation Majoon 10 g orally and Tila Baras-e-Aswad topically was given for 45 days. Primary Outcome Measures: Evaluation of prognosis with averaged PASI (Psoriasis Area and Severity Index) (EPAP) and dermatology life quality index (DLQI) were the outcome of the study and analyzed per protocol.
RESULTS: The data analysis of 30 patients who completed the study showed a statistically significant result in the EPAP scores (P < .05), which reduced from 1112.57 ± 988.45 at baseline to 1108.95 ± 988.87, 1107.71 ± 988.52, and 1105.57 ± 988.76 on 15th, 30th, and 45th day respectively. DLQI score reduced significantly (P < .05) from 18.60 ± 2.72 at baseline to 15.20 ± 2.90, 10.76 ± 2.07, and 8.00 ± 2.43 on 15th, 30th, and 45th day respectively. The test drugs were found to be tolerable without any adverse effects.
CONCLUSION: This study highlights the positive effect of Majoon and Tila Baras-e-Aswad combination formulation on the clinical efficacy, quality of life, and short-term prognosis in chronic plaque psoriasis patients, providing valuable insights for further research in a well-designed study.
PRIMARY STUDY OBJECTIVE: This study aimed to evaluate the efficacy of Majoon and Tila Baras-e-Aswad, two combination formulations, consisting of herbal, mineral, and animal drugs (antioxidants, anti-psoriatic, antihistaminic, antipruritic, and skin protection with healing activities), prescribed for the treatment of Baras-e-Aswad, having a plaque psoriasis-like diagnosis in Unani medicine.
METHODS/DESIGN: Open-label single-arm and single-center clinical study with pre-and post-treatment analysis.
SETTING: Conducted in National Institute of Unani Medicine (NIUM) Hospital, Bangalore, India.
PARTICIPANTS: A total of 36 patients with plaque psoriasis with mild to moderate severity and aged 18-60 were included.
INTERVENTIONS: The intervention formulation Majoon 10 g orally and Tila Baras-e-Aswad topically was given for 45 days. Primary Outcome Measures: Evaluation of prognosis with averaged PASI (Psoriasis Area and Severity Index) (EPAP) and dermatology life quality index (DLQI) were the outcome of the study and analyzed per protocol.
RESULTS: The data analysis of 30 patients who completed the study showed a statistically significant result in the EPAP scores (P < .05), which reduced from 1112.57 ± 988.45 at baseline to 1108.95 ± 988.87, 1107.71 ± 988.52, and 1105.57 ± 988.76 on 15th, 30th, and 45th day respectively. DLQI score reduced significantly (P < .05) from 18.60 ± 2.72 at baseline to 15.20 ± 2.90, 10.76 ± 2.07, and 8.00 ± 2.43 on 15th, 30th, and 45th day respectively. The test drugs were found to be tolerable without any adverse effects.
CONCLUSION: This study highlights the positive effect of Majoon and Tila Baras-e-Aswad combination formulation on the clinical efficacy, quality of life, and short-term prognosis in chronic plaque psoriasis patients, providing valuable insights for further research in a well-designed study.